This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk Patients | MicrobiomeTrials
← Back to trials NCT06306014
Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk Patients Recruiting PHASE1, PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2024-05-07Est. Completion: 2028-01-07
Enrollment target: 56 participantsLocations CH Annecy Genevois Service de Maladies infectieuses, Annecy, France Service d'hépato-gastroentérologie - CHU Estaing, Clermont-Ferrand, France CHU Grenoble Service Maladies infectieuses et tropicales, Grenoble, France CHU Lille Unité des Maladies Infectieuses et tropicales, Lille, France Service d'Hépato-gastroentérologie Hôpital de la Croix Rousse, Lyon, France APHM La Timone Service de Maladies infectieuses, Marseille, France Service d'hépato-gastroentérologie - Hôpital Saint Antoine (APHP), Paris, France Service d'infectiologie - Hôpital Nord / CHU Saint Etienne, Saint-Etienne, France Service de médecine interne - Pôle des maladies de l'appareil digestif - CHU de Toulouse, Toulouse, France Service de Maladies Infectieuses - CH de Valence, Valence, France Other microbiome trials you might be interested in Clostridium Difficile Clostridium Difficile Infections Clostridium Difficile Infection Recurrence Clostridioides Difficile Infection Clostridioides Difficile Infection Recurrence CDI C. Diff Infection Recurrent Clostridium Difficile Infection C.Difficile Diarrhea Diarrhea Infectious
The overall objective of the RESTORATiVE303 study is to evaluate the safety and the Clostridioides difficile infection (…
Huntsville, United States Est. completion Jun 2027
Intestinal Disease
The gut microbiota plays a crucial role in human health, influencing metabolism, immunity, and pathogen resistance. Rese…
Rome, Italy Est. completion Mar 10, 2027
Clostridium Difficile Infection
This is a Phase 1, first-in-human, double-blind, placebo-controlled, adaptive-design, single-site study, involving dose …
Multiple Locations Est. completion Aug 22, 2028